BUD23

Across TCGA pan-cancer cohorts, BUD23 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BUD23 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BUD23 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BUD23 expression acts as an unfavorable survival marker.

HNSC, SARC, and SKCM are the cancer types where BUD23 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.195	0.710	.019	18	view →
SARC	DFS	Median	All	0.101	0.632	.011	12	view →
SKCM	DFS	Median	All	0.209	0.728	.022	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

BUD23–HNSC (DFS)

Open the HNSC breakdown →